SEC Form 4 · accession 0001104659-26-075284
Aprea Therapeutics, Inc. · APRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabriela Gruia
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 17, 2026 · 7:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001781983
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 16, 2026 | A | 3,135 | $0.00 | A | 4,180 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $0.7293 | Jun 16, 2026 | A | 12,555 | A | — | Jun 16, 2036 | Common Stock | 12,555 | 12,555 | D |
Explanation of responses
- F1These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- F2The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.